GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Hansoh Pharmaceutical Group Co Ltd (HKSE:03692) » Definitions » EPS (Diluted)

Hansoh Pharmaceutical Group Co (HKSE:03692) EPS (Diluted) : HK$0.57 (TTM As of Dec. 2023)


View and export this data going back to 2019. Start your Free Trial

What is Hansoh Pharmaceutical Group Co EPS (Diluted)?

Hansoh Pharmaceutical Group Co's Earnings per Share (Diluted) for the six months ended in Dec. 2023 was HK$0.33. Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was HK$0.57.

Hansoh Pharmaceutical Group Co's EPS (Basic) for the six months ended in Dec. 2023 was HK$0.36. Its EPS (Basic) for the trailing twelve months (TTM) ended in Dec. 2023 was HK$0.60.

Hansoh Pharmaceutical Group Co's EPS without NRI for the six months ended in Dec. 2023 was HK$0.31. Its EPS without NRI for the trailing twelve months (TTM) ended in Dec. 2023 was HK$0.55.

During the past 12 months, Hansoh Pharmaceutical Group Co's average EPS without NRIGrowth Rate was 14.00% per year. During the past 3 years, the average EPS without NRIGrowth Rate was 2.00% per year. During the past 5 years, the average EPS without NRI Growth Rate was 4.60% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

During the past 8 years, Hansoh Pharmaceutical Group Co's highest 3-Year average EPS without NRI Growth Rate was 22.00% per year. The lowest was -3.10% per year. And the median was 12.50% per year.


Hansoh Pharmaceutical Group Co EPS (Diluted) Historical Data

The historical data trend for Hansoh Pharmaceutical Group Co's EPS (Diluted) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Hansoh Pharmaceutical Group Co EPS (Diluted) Chart

Hansoh Pharmaceutical Group Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EPS (Diluted)
Get a 7-Day Free Trial 0.52 0.52 0.54 0.49 0.57

Hansoh Pharmaceutical Group Co Semi-Annual Data
Dec16 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
EPS (Diluted) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.29 0.26 0.25 0.24 0.33

Competitive Comparison of Hansoh Pharmaceutical Group Co's EPS (Diluted)

For the Drug Manufacturers - Specialty & Generic subindustry, Hansoh Pharmaceutical Group Co's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Hansoh Pharmaceutical Group Co's PE Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Hansoh Pharmaceutical Group Co's PE Ratio distribution charts can be found below:

* The bar in red indicates where Hansoh Pharmaceutical Group Co's PE Ratio falls into.



Hansoh Pharmaceutical Group Co EPS (Diluted) Calculation

EPS (Diluted) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Diluted EPS takes into account all of the outstanding dilutive securities that could potentially be exercised (such as stock options and convertible preferred stock) and shows how such an action would impact earnings per share.

Hansoh Pharmaceutical Group Co's Diluted EPS for the fiscal year that ended in Dec. 2023 is calculated as

Diluted EPS (A: Dec. 2023 ) = (Net Income - Preferred Dividends) / Shares Outstanding (Diluted Average)
=(3584.864-0)/6019.650
=0.60

Hansoh Pharmaceutical Group Co's Diluted EPS for the quarter that ended in Dec. 2023 is calculated as

Diluted EPS (Q: Dec. 2023 )=(Net Income - Preferred Dividends) / Shares Outstanding (Diluted Average)
=(2175.149-0)/6095.751
=0.36

EPS (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was HK$0.57

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Hansoh Pharmaceutical Group Co  (HKSE:03692) EPS (Diluted) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.


Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.


Hansoh Pharmaceutical Group Co EPS (Diluted) Related Terms

Thank you for viewing the detailed overview of Hansoh Pharmaceutical Group Co's EPS (Diluted) provided by GuruFocus.com. Please click on the following links to see related term pages.


Hansoh Pharmaceutical Group Co (HKSE:03692) Business Description

Traded in Other Exchanges
Address
287 Xiangke Road, Pudong New District, Shanghai, CHN, 201210
Hansoh Pharmaceutical Group Co Ltd is a research and development-driven pharmaceutical company in China. The company holds a broad, diversified drug portfolio in CNS diseases, oncology, anti-infectives, and diabetes. Further, it also focuses on metabolic diseases and anti-tumor. The majority of revenue is generated from the sale of pharmaceutical products in Mainland China.

Hansoh Pharmaceutical Group Co (HKSE:03692) Headlines

No Headlines